Welcome to our dedicated page for Vistagen Therapeutics SEC filings (Ticker: VTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vistagen Therapeutics, Inc. filings document regulatory and corporate events for a Nasdaq-listed late clinical-stage biopharmaceutical company. Recent Form 8-K disclosures cover clinical program updates for fasedienol in the PALISADE social anxiety disorder program, FDA-related developments for refisolone under an IND application, and Regulation FD materials such as corporate presentations.
The company’s filings also record governance and capital-structure matters, including board departures, Audit Committee composition and Nasdaq listing-rule compliance, employee retention awards under the Amended and Restated 2019 Omnibus Equity Incentive Plan, and workforce and cash-management actions tied to clinical-development priorities.
Vistagen Therapeutics, Inc. is the issuer of Common Stock, par value $0.001 per share, CUSIP 92840H400. OrbiMed Advisors LLC and OrbiMed Capital LLC report that they now beneficially own 0 shares of this common stock, representing 0.0% of the class. They report no sole or shared voting or dispositive power over any Vistagen common shares, confirming ownership of 5 percent or less of the class and that they hold 0.0% on behalf of other persons.
Vistagen Therapeutics, Inc. received an updated Schedule 13G/A from TCG Crossover funds and Chen Yu regarding beneficial ownership of its common stock through warrants. The filing reports TCG Crossover I and its GP as beneficially owning 740,101 shares issuable upon exercise of Tranche I and Tranche II Warrants, representing 1.8% of the common stock on an as-converted basis. TCG Crossover II and its GP are reported as beneficially owning 2,220,303 warrant shares, or 5.1%. Chen Yu, as sole managing member of both general partners, may be deemed to beneficially own 2,960,404 warrant shares, or 6.7%, all subject to a 9.99% Beneficial Ownership Limitation that restricts warrant exercises above that level. The ownership calculations use 41,032,453 shares of common stock outstanding as of June 12, 2026, plus the respective warrant shares assumed exercised.
Vistagen Therapeutics, Inc. reported a net loss of $13.0 million for the quarter ended June 30, 2026, improving from a $15.1 million loss a year earlier. Revenue rose to $1.5 million from $0.2 million, driven by sublicense and collaboration activity. Operating expenses remained high at $14.8 million, largely for research and development of its pherine-based neuroscience pipeline.
Cash, cash equivalents and marketable securities totaled $31.7 million, down from $45.4 million at March 31, 2026, with $14.7 million used in operating activities during the quarter. The company disclosed substantial doubt about its ability to continue as a going concern within one year without additional financing and expects continuing losses. Nasdaq granted an extension until February 1, 2027 to regain compliance with the $1.00 minimum bid price requirement.
Vistagen advanced multiple clinical programs. For lead candidate fasedienol in social anxiety disorder, one Phase 3 trial (PALISADE-2) was previously positive, while others did not meet primary endpoints; post-hoc analyses showed nominal benefits in very severe patients. The company believes it now meets ICH E1 exposure recommendations and plans FDA discussions on a potential registrational path. Refisolone and itruvone also progressed, with refisolone cleared to proceed in U.S. Phase 2 for menopausal hot flashes.
Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson and Michael Kramarz report beneficial ownership of Vistagen Therapeutics, Inc. common stock on a passive Schedule 13G basis. As of June 30, 2026, they may be deemed to beneficially own 4,244,590 shares of common stock.
This consists of 2,788,620 common shares, Tranche 1 Warrants to purchase up to 1,394,310 shares, and Tranche 2 Warrants to purchase up to 61,660 shares, representing 9.9% of the class. The Tranche 1 and Tranche 2 Warrants are subject to a 9.99% Beneficial Ownership Limitation, so an additional 1,628,354 Tranche 2 Warrants are excluded from the reported beneficial ownership.
Vistagen Therapeutics reported fiscal 2027 first quarter results and a corporate update centered on its intranasal pherine pipeline. Revenue was $1.5 million, mainly from recognizing $1.2 million tied to the expiration of an exclusivity period under a Fuji Pharma agreement. Research and development expense was $10.9 million and general and administrative expense was $3.9 million, both modestly lower than a year earlier as the company executes cash preservation initiatives.
Net loss was $13.0 million, improving from $15.1 million in the prior-year quarter. Cash, cash equivalents, and marketable securities totaled $31.7 million as of June 30, 2026, which Vistagen believes will fund operations into 2027 but not for more than a year from now. Clinically, the lead candidate fasedienol did not meet the primary endpoint in the overall PALISADE-4 Phase 3 population, but exploratory and post-hoc analyses in patients with very severe social anxiety showed nominally statistically significant improvements versus placebo, with a favorable safety profile. The company has achieved ICH-recommended exposure levels and is planning FDA discussions on a potential Phase 3 registrational path, while also advancing itruvone and refisolone and adding experienced neuroscience leadership.
Vistagen Therapeutics, Inc. reported topline data from an exploratory, three-arm, randomized, double-blind, placebo-controlled Phase 2 study (N=61) of intranasal fasedienol for the acute treatment of social anxiety disorder during a public speaking challenge, comparing two 3.2 µg doses ten minutes apart with a single 3.2 µg dose and placebo.
The study met its safety objective, with repeat dosing showing safety and tolerability comparable to single-dose administration and no new safety findings. On the primary endpoint, LS mean change in Subjective Units of Distress (SUDS) from baseline to challenge, pooled fasedienol reduced SUDS by 15.0 versus 6.8 for placebo, but between-group differences were not statistically significant. In a prespecified subgroup with very severe social anxiety (Liebowitz Social Anxiety Scale ≥95), pooled fasedienol showed a larger SUDS reduction of 16.2 versus 1.6 for placebo with nominal p=0.04. Responder rates on CGI-I and PGI-C were directionally higher for fasedienol, with repeat-dose CGI-I responders at 47% versus 19% for placebo. An exploratory analysis of anticipatory anxiety found pooled fasedienol cut SUDS by 13.8 versus 0.9 for placebo (nominal p=0.03), with repeat dosing at 19.3 (p=0.01). These exploratory findings, which include nominally statistically significant effects in very severe patients, will inform upcoming discussions with the FDA about a potential registrational pathway for fasedienol, subject to the cautions and risks described.
Vistagen Therapeutics, Inc. reports that Nasdaq has granted a 180-day extension, until February 1, 2027, to regain compliance with the $1.00 per share Minimum Bid Price Requirement for its common stock to remain listed on the Nasdaq Capital Market.
The extension does not immediately affect the stock’s listing, which remains fully effective. Vistagen has informed Nasdaq it intends to cure the deficiency within the extension period. If compliance is not restored by that deadline, the common stock would be subject to delisting, and any appeal to a Nasdaq Hearing Panel is not assured of success.
Vistagen Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on September 10, 2026 on three items: electing four continuing directors, a non-binding advisory vote on Named Executive Officer compensation, and ratification of KPMG LLP as independent auditor for the fiscal year ending March 31, 2027.
Holders of common stock at the July 22, 2026 record date, when 44,376,911 shares were outstanding, are entitled to one vote per share. The board currently has six members and will decrease to four after two directors do not stand for re-election, while a search is underway for additional independent candidates. The proxy describes director fees, heavy use of stock options in director and executive pay, a clawback policy, insider-trading and anti-hedging rules, and a prior Say-on-Pay vote that received over 97% support. For fiscal 2026, no performance-based cash bonuses or salary increases were granted to NEOs, though certain newer executives received retention bonuses and inducement option awards.
Williamson Douglas J reported acquisition or exercise transactions in this Form 4 filing.
Vistagen Therapeutics director Douglas J. Williamson received a grant of 40,826 stock options on July 29, 2026, each exercisable at $0.2433 per share for common stock. The options, granted in connection with his appointment to the Board under the company’s 2019 equity plan, vest in three equal annual installments beginning one year after grant and expire on July 29, 2036. Following this award, he holds 40,826 options, and no sales or purchases of common shares were reported.
Vistagen Therapeutics, Inc. filed a Form 3 initial statement of beneficial ownership for Douglas J Williamson, who is identified as a director of the company. The filing reports no transactions and does not list any equity holdings or derivative positions for him.